Chemistry:VK2809
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | VK-2809; MB07811 |
| Identifiers | |
| |
| CAS Number | |
| DrugBank | |
| UNII | |
| Chemical and physical data | |
| Formula | C28H32ClO5P |
| Molar mass | 514.98 g·mol−1 |
VK2809 (formerly known as MB07811) is a thyromimetic prodrug whose active form is selective for the THR-β isoform. It is being developed by Viking Therapeutics in a phase II trial for the treatment of nonalcoholic steatohepatitis[1][2] and is also being investigated for glycogen storage disease type Ia.[3]
References
- ↑ "VK2809". https://vikingtherapeutics.com/pipeline/metabolic-disease-program/vk2809/.
- ↑ Alkhouri, Naim (1 February 2020). "Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)" (in en). Expert Opinion on Investigational Drugs 29 (2): 99–101. doi:10.1080/13543784.2020.1708899. ISSN 1354-3784. https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1708899.
- ↑ Zhou, Jin; Waskowicz, Lauren R.; Lim, Andrea; Liao, Xiao-Hui; Lian, Brian; Masamune, Hiroko; Refetoff, Samuel; Tran, Brian et al. (1 August 2019). "A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia". Thyroid 29 (8): 1158–1167. doi:10.1089/thy.2019.0007. ISSN 1050-7256. PMID 31337282.
 |  |
